5 Best Stocks to Buy Under $20 According to Jeremy Green’s Redmile Group
In this piece, we will take a look at the top five best stocks to buy under $20 according to Jeremy Green's Redmile Group.
Amicus Therapeutics Inc. (FOLD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 27,555,845 | $260,954 | +4% | 5.22% |
| 2. | Redmile Group Jeremy Green | 22,329,386 | $211,459 | -2% | 6.6% |
| 3. | VenBio Select Advisor Kurt Von Emster | 20,500,000 | $194,135 | +11% | 3.54% |
| 4. | Palo Alto Investors William Leland Edwards | 9,903,761 | $93,789 | -3% | 7.25% |
| 5. | D E Shaw D. E. Shaw | 3,044,438 | $28,831 | +11% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.49 | 1,500 | Director | 65,082 | 2021-11-01 | Filing | |
| $9.56 | 1,500 | Director | 63,582 | 2021-10-01 | Filing | |
| $11.41 | 1,500 | Director | 62,082 | 2021-09-01 | Filing | |
| $9.28 | 1,500 | Director | 60,582 | 2021-08-02 | Filing | |
| $9.24 | 1,500 | Director | 47,467 | 2021-06-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.00 | 16,410 | Officer, Director | 689,618 | 2022-06-21 | Filing | |
| $10.00 | 11,122 | Officer | 291,830 | 2022-06-21 | Filing | |
| $9.00 | 4,396 | Officer | 345,507 | 2022-06-17 | Filing | |
| $8.01 | 10,468 | Officer, Director | 922,339 | 2022-06-15 | Filing | |
| $8.00 | 11,346 | Officer, Director | 932,807 | 2022-06-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 561,574 | $5,318,106 | 0% | |
| 2. | 269,026 | $2,547,675 | 0% | |
| 3. | 26,619,107 | $252,083 | 0.04% | |
| 4. | 25,657,170 | $242,973 | 0% | |
| 5. | 19,593,001 | $185,546 | 0% |
News See All
Top 10 Biotech Stocks to Buy According to Jeremy Green’s Redmile Group
In this article, we will discuss the top 10 biotech stocks to buy according to Jeremy Green's Redmile Group.
Were Hedge Funds Right About Amicus Therapeutics, Inc. (FOLD)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Funds Are Selling Amicus Therapeutics, Inc. (FOLD)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
5 Pharmaceutical Stocks to Buy Under $20 According to Jeremy Green’s Redmile Group
In this article, we discuss the 5 pharmaceutical stocks to buy under $20 according to Jeremy Green's Redmile Group portfolio based on Q3 holdings of the fund.
Top Investors’ Stock Portfolio: 5 Small-Cap Stocks To Buy
In this article, we discuss the best small-cap stocks to buy.
15 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors
In this article, we will take a look at 15 biotech and pharmaceutical stocks to buy according to Palo Alto Investors.
10 Best Biotech Stocks to Buy According to Joseph Edelman’s Perceptive Advisors
In this article, we will discuss the 10 best biotech stocks to buy according to Joseph Edelman’s Perceptive Advisors.
Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy?
After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed...
Here is What Hedge Funds Think About Amicus Therapeutics, Inc. (FOLD)
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade.
Billionaire Hedge Funds
